The land of Africa is the second largest continent in the world in both square mileage and population. Thus, it also has widespread disease and in turn, is a huge testing bed for new medications and procedures. This week Merck and Qiagen NV have announced collaboration in Rwanda to battle cervical cancer.
Rwanda will be the first country in the world to implement a cervical cancer prevention program in history.
Mark Feinberg, chief public health and science officer at Merck Vaccines stated:
“Over 85% percent of cervical cancer cases occur in the world’s poorest countries, having an impact on the women affected, their families and their communities.”